Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07762404
Reconstruction of First Web Space After Trauma and BurnSohag UniversityNot Yet RecruitingNot Applicable
NCT07762404Not Yet Recruiting
Not Applicable
Reconstruction of First Web Space After Trauma and BurnSohag University
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07764094
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery DiseaseNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764094Recruiting
—
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery...Nanjing First Hospital, N...
NCT07763379
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKAGE FOLLOWING PRIMARY REPAIR IN GASTROINTESTINAL SURGERYSohag UniversityRecruiting
NCT07763379Recruiting
—
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKA...Sohag University
NCT07763678
Efficacy of Ultrasound-Guided Combined Greater Occipital Nerve Block and Greater Auricular Nerve Block Versus Greater Occipital Nerve Block Alone in the Management of Chronic MigraineAssiut UniversityNot Yet RecruitingPhase 4
NCT07763678Not Yet Recruiting
Phase 4
Efficacy of Ultrasound-Guided Combined Greater Occipital Nerve Block and Greater...Assiut University
NCT07762872
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDChifeng Municipal HospitalRecruiting
NCT07762872Recruiting
—
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in...Chifeng Municipal Hospita...
NCT07763145
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy: A Randomized Control TrialHayatabad Medical ComplexNot Yet RecruitingNot Applicable
NCT07763145Not Yet Recruiting
Not Applicable
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resisti...Hayatabad Medical Complex
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07763808
Surgical Treatment for Gingival Recessions After Orthodontic TreatmentAziz Aliyev Azerbaijan State Advanced Training Institute for DoctorsRecruitingPhase 2
NCT07763808Recruiting
Phase 2
Surgical Treatment for Gingival Recessions After Orthodontic TreatmentAziz Aliyev Azerbaijan St...
NCT07762027
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus InfectionAssembly BiosciencesNot Yet RecruitingPhase 2
NCT07762027Not Yet Recruiting
Phase 2
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Part...Assembly Biosciences
NCT07762807
Colchicine And Dialysis Patients; a Feasibility StudyGuy's and St Thomas' NHS Foundation TrustRecruitingNot Applicable
NCT07762807Recruiting
Not Applicable
Colchicine And Dialysis Patients; a Feasibility StudyGuy's and St Thomas' NHS...
NCT07761988
The FamilyStrong Pilot Randomized TrialAmerican Cancer Society, Inc.Not Yet RecruitingNot Applicable
NCT07761988Not Yet Recruiting
Not Applicable
The FamilyStrong Pilot Randomized TrialAmerican Cancer Society,...
NCT07762040
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting Multiple SclerosisAssiut UniversityNot Yet Recruiting
NCT07762040Not Yet Recruiting
—
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting...Assiut University
NCT07763990
THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FILLERHallura Ltd.RecruitingNot Applicable
NCT07763990Recruiting
Not Applicable
THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FI...Hallura Ltd.
NCT07763548
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Minimize Propofol Injection PainErasme University HospitalNot Yet RecruitingPhase 4
NCT07763548Not Yet Recruiting
Phase 4
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Mini...Erasme University Hospita...
NCT07762586
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)Rutgers, The State University of New JerseyRecruitingPhase 2
NCT07762586Recruiting
Phase 2
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NA...Rutgers, The State Univer...
NCT07762430
Food Noise Survey Development and Validation in Hindi and English-Speaking AdultsDiabetes Foundation, IndiaNot Yet Recruiting
NCT07762430Not Yet Recruiting
—
Food Noise Survey Development and Validation in Hindi and English-Speaking Adult...Diabetes Foundation, Indi...
NCT07763366
Pain Neuroscience Education and Graded Motor Imagery Combined With Conventional Physiotherapy on Diabetic Adhesive CapsulitisRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07763366Not Yet Recruiting
Not Applicable
Pain Neuroscience Education and Graded Motor Imagery Combined With Conventional...Riphah International Univ...
NCT07762755
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen HospitalNot Yet RecruitingPhase 4
NCT07762755Not Yet Recruiting
Phase 4
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen Hospital
NCT07762833
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisGalderma R&DNot Yet RecruitingPhase 3
NCT07762833Not Yet Recruiting
Phase 3
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Sub...Galderma R&D
Result Breakdown
Not yet recruiting11 (55%)
Recruiting7 (35%)
Unknown1 (5%)
Active, not recruiting1 (5%)
not_applicable6 (30%)
Not Specified6 (30%)
Phase 43 (15%)
Phase 23 (15%)
Phase 11 (5%)
Phase 31 (5%)